CD206 agonist for tumor microenvironment modulation
Riptide Bioscience presents a novel CD206 agonist that targets tumor-associated macrophages to reverse immune suppression and boost anti-tumor immunity. This technology involves proprietary peptides and a companion diagnostic radioligand for real-time macrophage assessment.
Overview
Riptide Bioscience introduces an innovative approach to modulating the tumor microenvironment by targeting CD206 on tumor-associated macrophages (TAMs). This solution involves the use of proprietary synthetic peptides, termed "RP peptides," which aim to repolarize M2-like macrophages to an M1-like phenotype, thereby enhancing the immune response against tumors. A companion diagnostic, a CD206 peptide-radioligand, has also been developed to assess macrophage infiltration in real-time.
Technical specifications
Key features:
- RP Peptides: Synthetic peptides designed to bind CD206 and reprogram M2 macrophages to an M1 phenotype.
- CD206 Peptide-Radioligand: Companion diagnostic tool for real-time monitoring of macrophage activity in tumors.
- Cellular Effects: Demonstrated influence on T-cells, NK cells, and dendritic cells, with experiments planned to further elucidate these interactions.
Proposed Experiments:
- High-throughput multiplex ELISA to identify T-cell activation cytokine signatures.
- Validation of RP peptides' ability to reactivate exhausted CD8+ T-cells in vitro.
- Single-cell spatial transcriptomics to study cellular crosstalk and immune cell activation.
Technology readiness level
The technology is currently at TRL 5, indicating that it has been validated in relevant environments. Ongoing experiments aim to further assess and optimize the therapeutic potential and interactions of RP peptides and the radioligand.
About Riptide Bioscience Inc.
Riptide Bioscience Inc. is a biopharmaceutical company that develops engineered peptide therapeutics based on Host Defense Peptides (HDPs). By identifying the key structures of these naturally occurring proteins, the company uses proprietary methods to design synthetic peptides with significantly enhanced efficacy. These engineered peptides act through electrostatic attraction to microbial cell surfaces, allowing them to combat infections by penetrating bacterial biofilms that often resist conventional antibiotics. Additionally, the company has developed peptides designed to modulate inflammatory processes and target tumor-associated macrophages within the tumor microenvironment to inhibit tumor growth and metastasis.
These therapeutic candidates are intended to address significant medical challenges, including antibiotic-resistant infections, chronic inflammatory conditions, and various solid organ cancers. The company’s approach is supported by preclinical data from animal models and independent research, including collaborations with academic institutions and grants from organizations such as the National Cancer Institute, the National Eye Institute, and the Department of Defense. Riptide focuses on developing drug candidates for topical, subcutaneous, or other administrative applications in areas such as wound healing, pulmonary fibrosis, and oncology, while actively seeking pharmaceutical partnerships to advance its proprietary pipeline.
delivered to your inbox.